News

Vertex Plunges Around 24% in Six Months: How to Play the Stock

Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.

Why This Biotech Company Could Be a Growth Stock Powerhouse

This biotech is a leader in the treatment of cystic fibrosis, and that’s helped earnings explode higher over the years. The ...

Three scientists who revolutionized cystic fibrosis treatment win prestigious Lasker award

Their research led to the development of a drug that nearly doubles the life expectancy for adult cystic fibrosis patients.

Vertex Pharmaceuticals Incorporated: Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year's Lasker~DeBakey Clinical Medical Researc ...

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named ...